Quarterly intravenous injection of ibandronate to treat osteoporosis in postmenopausal women

Philip SambrookUniversity of Sydney, SydneyAbstract: Osteoporosis is a chronic condition that generally requires long-term therapy for fracture risk reduction to become apparent. Although the bisphosphonates have made a major contribution to how clinicians manage osteoporosis, compliance with therap...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Philip Sambrook
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2007
Materias:	Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/278f4da4b1c54daf85c4234cf9946289
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:278f4da4b1c54daf85c4234cf9946289
record_format	dspace
spelling	oai:doaj.org-article:278f4da4b1c54daf85c4234cf99462892021-12-02T06:25:58ZQuarterly intravenous injection of ibandronate to treat osteoporosis in postmenopausal women1178-1998https://doaj.org/article/278f4da4b1c54daf85c4234cf99462892007-04-01T00:00:00Zhttps://www.dovepress.com/quarterly-intravenous-injection-of-ibandronate-to-treat-osteoporosis-i-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Philip SambrookUniversity of Sydney, SydneyAbstract: Osteoporosis is a chronic condition that generally requires long-term therapy for fracture risk reduction to become apparent. Although the bisphosphonates have made a major contribution to how clinicians manage osteoporosis, compliance with therapy has generally been less in the real-world setting than seen in clinical trials. Less-frequently administered dosage regimens or nonoral routes may enhance compliance and so maximize the therapeutic benefit of bisphosphonates. Ibandronate is a nitrogen-containing bisphosphonate, whose high potency allows it to be administered orally or intravenously with extended dosing intervals. This paper will review the role of intravenous ibandronate in the treatment of postmenopausal osteoporosis.Keywords: osteoporosis, bisphosphonates, intravenous, fracturePhilip SambrookDove Medical PressarticleGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 2, Pp 65-72 (2007)
institution	DOAJ
collection	DOAJ
language	EN
topic	Geriatrics RC952-954.6
spellingShingle	Geriatrics RC952-954.6 Philip Sambrook Quarterly intravenous injection of ibandronate to treat osteoporosis in postmenopausal women
description	Philip SambrookUniversity of Sydney, SydneyAbstract: Osteoporosis is a chronic condition that generally requires long-term therapy for fracture risk reduction to become apparent. Although the bisphosphonates have made a major contribution to how clinicians manage osteoporosis, compliance with therapy has generally been less in the real-world setting than seen in clinical trials. Less-frequently administered dosage regimens or nonoral routes may enhance compliance and so maximize the therapeutic benefit of bisphosphonates. Ibandronate is a nitrogen-containing bisphosphonate, whose high potency allows it to be administered orally or intravenously with extended dosing intervals. This paper will review the role of intravenous ibandronate in the treatment of postmenopausal osteoporosis.Keywords: osteoporosis, bisphosphonates, intravenous, fracture
format	article
author	Philip Sambrook
author_facet	Philip Sambrook
author_sort	Philip Sambrook
title	Quarterly intravenous injection of ibandronate to treat osteoporosis in postmenopausal women
title_short	Quarterly intravenous injection of ibandronate to treat osteoporosis in postmenopausal women
title_full	Quarterly intravenous injection of ibandronate to treat osteoporosis in postmenopausal women
title_fullStr	Quarterly intravenous injection of ibandronate to treat osteoporosis in postmenopausal women
title_full_unstemmed	Quarterly intravenous injection of ibandronate to treat osteoporosis in postmenopausal women
title_sort	quarterly intravenous injection of ibandronate to treat osteoporosis in postmenopausal women
publisher	Dove Medical Press
publishDate	2007
url	https://doaj.org/article/278f4da4b1c54daf85c4234cf9946289
work_keys_str_mv	AT philipsambrook quarterlyintravenousinjectionofibandronatetotreatosteoporosisinpostmenopausalwomen
_version_	1718399923583451136

Quarterly intravenous injection of ibandronate to treat osteoporosis in postmenopausal women

Ejemplares similares